Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

13.42 +0.51 (+3.95%)
Streaming Delayed Price Updated: 1:14 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 753,734
Open 13.11
Bid (Size) 13.41 (2)
Ask (Size) 13.43 (4)
Prev. Close 12.91
Today's Range 12.90 - 13.60
52wk Range 11.82 - 41.93
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. 
Via InvestorPlace
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-62.70%
-62.70%
1 Month
-14.82%
-14.82%
3 Month
-38.16%
-38.16%
6 Month
-44.18%
-44.18%
1 Year
-63.38%
-63.38%

More News

Read More
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Earnings Preview For Amylyx Pharma
Via Benzinga
Expert Ratings for Amylyx Pharma
Via Benzinga
A Preview Of Amylyx Pharma's Earnings
Via Benzinga
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX)
From Kirby McInerney LLP
Via Business Wire
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Amylyx Crashes 26% As New ALS Drug Faces A Barrage Of Troubles
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Under-the-Radar Biotech Stocks to Buy in 2023
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
Via The Motley Fool
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France
From Amylyx Pharmaceuticals
Via Business Wire
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Via InvestorPlace
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.